Cambridge, UK, 24 th April 2026 - Amphista Therapeutics (“the Company” or “Amphista”), a leader in the discovery and development of non-cereblon/non-VHL Targeted Glue™ degraders, today announces the ...

IBA gathers the most knowledgeable proton therapy experts coming from the most prestigious cancer care institutions. Louvain-La-Neuve, Belgium, April 24, 2026 –IBA (Ion Beam App ...

Coartem Baby was developed by Novartis with the scientific and financial support of MMV, and as part of the PAMAfrica consortium, which is co-funded by the European & Developing Countries Clinical ...

Vistin Pharma ASA (VISTN) today announces the financial results for the first quarter of 2026.

CUV107 to compare SCENESSE® with adjunct NB-UVB vs NB-UVB monotherapy MELBOURNE, Australia, April 24, 2026 (GLOBE NEWSWIRE) -- CLINUVEL PHARMACEUTICALS LTD today announced that the European Medicines ...

Groundbreaking AAV-based gene therapy offers potential treatment for patients with OTOF gene-associated severe-to-profound and profound hearing loss. White Oak, Md., April 24, 202 ...

If the Company does not regain compliance with the Minimum Bid Price Rule by October 19, 2026, Nasdaq has informed the Company that it will provide written notification that the Company’s Class A ...

With April designated as Alcohol Awareness Month, Oxford Treatment Center, a leading provider of addiction and co-occurring disorder treatment in Mississippi, is sounding the alarm over a concerning ...

Live audio of the webcast will be available on the “Investors” section of the company website at investors.cytekbio.com.

Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced that it ...

In the United States, ONS-5010/LYTENAVA™ (bevacizumab-vikg) is investigational. If approved in the United States, ONS-5010/LYTENAVA™, would be the first approved ophthalmic formulation of bevacizumab ...

Total VITAS admissions increased 6.9% in the first quarter of 2026 compared to the first quarter of 2025. In the first quarter of 2026, VITAS accrued $2.4 million in Medicare Cap billing limitation.